APA WF # 25-25 Opioid Overdose Reversal Agents

The proposed policy changes are being promulgated as Permanent Rules.

The proposed revisions update coverage language to allow for new opioid overdose reversal agents as they become available on the market. Current policy specifies coverage for Naloxone by name, which was appropriate when it was the only available option. As additional opioid overdose reversal agents are now available, the revised language broadens coverage to include other clinically appropriate agents, ensuring timely access and alignment with evolving federal and clinical standards.

Please view the draft regulatory text here and submit feedback via the comment box.

Pursuant to 75 O.S. §303(D), a rule impact statement will be posted here beginning December 30, 2025. Individuals may also request a copy using the comment box, and the statement will be provided on December 30, 2025.

Proposed Policy Timeline

Circulation Date: 12/15/2025

Medical Advisory Committee: 1/8/2026

Comment Due Date: 1/15/2026

Public Hearing: 1/15/2026

Board Meeting: 1/21/2026

After you submit your comment, you should be re-directed to a confirmation page. If you are not, please submit your comment through e-mail to federal.authorities@okhca.org.

Please note that all comments must be reviewed and approved prior to posting. Approved comments will be posted Monday through Friday between the hours of 7:30 a.m. – 4 p.m. Any comments received after 4 p.m. will be posted on the following business day.